Introduction {#sec1}
============

Cancer is a major global health problem and it is worse in case of low- and middle-income developing countries. According to India's National Cancer Registry Program (NCRP), 1.45 million cases would occur in 2016 with 0.74 million deaths in India. This is expected to rise to 1.73 million cases and 0.88 million deaths in 2020 \[[@B1],[@B2]\]. Cancer is considered the disease of abnormal cell division. Besides, many environmental cofactors (smoking, use of alcohol, exposure to UV radiations, infections with certain viruses) and host genetic makeup has been recognized as a pivotal risk factor for human cancers.

India ranks third in the world in terms of incidence rate of cancer cases amongst women after China and the U.S.A. According to the Globocan report 2012, there were ∼232000 breast cancer cases registered in the U.S.A., however in India, 145000 new cases were reported. The burden of breast cancer in India is approximately two-thirds of that of the U.S.A. and is growing progressively \[[@B3]\]. Breast cancer is one of the most common malignancies in women worldwide, and each year more than 1 million new cases are diagnosed \[[@B4]\]. The main risk factors for breast cancer are genetic predisposition, lifestyle, and environment \[[@B5]\]. Genetic polymorphisms have been identified as one of the crucial factor for determining inter-individual susceptibility to cancer \[[@B8]\]. The clinical importance of *CCND1* gene lies in the fact that 5--20% of breast cancer cases present with either amplified or deleted version of the gene \[[@B9],[@B10]\]. *CCND1* also has documented oncogenic characteristics by manipulating the regulation of cell cycle machinery particularly at the transition phase of G~1~/S \[[@B11],[@B12]\]. Cyclin D1 (CCND1) protein is found to be overexpressed in more than 50% of breast cancer cases \[[@B13]\]. An important functional single nucleotide polymorphism (SNP) in *CCND1* gene (rs9344) G870A, may influence the breast cancer development \[[@B14]\]. Esophageal cancer is the eighth most common cancer overall. In 2012, worldwide, 456000 new cases have been estimated (3.2% of all incidence cancer cases). It is the sixth most common cause of death from cancer, with an estimated 400000 deaths in 2012 (4.9% of all cancer deaths) \[[@B3]\]. It is one of the most common and lethal type of cancer worldwide, with \<20% of 5-year survival rate \[[@B15]\]. Colorectal cancer is the third most commonly diagnosed cancer in men and second in women, with \>1.4 million new cases annually \[[@B16]\]. Geographical deviation in the incidence rates has been observed as developed world contributes to \>50% of the cases. Though, mortality is more in the developing countries due to insufficient resources and health infrastructure \[[@B17]\]. In India, the age standardized rate (ASR) for colorectal cancer is 7.2 per 100000 men and 5.1 per 100000 women \[[@B3]\].

*CCND1* is a key cell cycle regulatory gene which governs the G~1~/S checkpoint in cell cycle. It is one of the most frequently altered molecules in human carcinogenesis. A common G/A SNP \[dbSNP ID rs9344\] was first described by Betticher et al. (1995) \[[@B18]\]. This SNP rs9344 is located at codon 242 in the exon-4/intron boundary of *CCND1* and responsible for alternate splicing of transcripts with different half-lives \[[@B18]\]. Since then many case--control studies have been conducted to explore the potential association between *CCND1* SNP (rs9344) and cancer susceptibility. Occurrence of this nucleotide variation has been found to be coupled with the risk of various cancers including cervical, breast, oral, esophageal, lung, urinary bladder, prostate, and colorectal \[[@B19]\]. The outcomes of these studies were inconsistent in different ethnic groups. To overcome this conflict, several meta-analyses have been performed worldwide to see the effect of *CCND1* polymorphism and risk for different types of cancer \[[@B30]\]. To the best of our knowledge, no report is available from India addressing the impact of *CCND1* SNP and overall cancer risk. Hence, we aimed to investigate the role of *CCND1* polymorphism G870A (rs9344) in overall cancer susceptibility amongst Indian population by conducting this meta-analysis. The present data could be helpful in enriching the existing knowledge with respect to involvement of *CCND1* polymorphism and cancer susceptibility in Indian population.

Methods {#sec2}
=======

Literature search strategy {#sec2-1}
--------------------------

*Pubmed* and *Embase* databases were searched with the keywords '*CCND1*', 'Cyclin D1', 'SNP', 'cancer', 'India', and 'polymorphism' for literature published till September 2016. All studies included in the present meta-analysis met the following inclusion and exclusion criteria.

Inclusion criteria {#sec2-2}
------------------

\(i\) Prospective or case--control studies involving association analysis between *CCND1* SNP G870A (rs9344) and cancer susceptibility, (ii) studies included Indian population, (iii) genotypic and allelic details are provided for both the cases and control groups, (iv) full text available, and (v) articles published in English language.

Exclusion criteria {#sec2-3}
------------------

\(i\) Studies published on populations other than Indian, (ii) articles published in languages except English, and (iii) articles not providing genotypic and allelic details.

Data retrieval {#sec2-4}
--------------

Data from all eligible studies were retrieved independently by two investigators (N.T. and S.K.). The retrieved data incorporated the following details: (i) PubMed IDentifier (PMID), (ii) name of the first author, (iii) year of publication, (iv) country, (v) sources of controls, (vi) methods for genotyping, and (vii) frequency of genotypic and allelic data.

Quality assessment {#sec2-5}
------------------

Quality of the included studies was assessed by assigning the quality scores as previously mentioned by He et al. (2014) \[[@B36]\]. The scores were assigned to each qualified studies between 0 and 10. Studies with \>5 scores were included for the further analyses (Supplementary Table S1).

Meta-analysis {#sec2-6}
-------------

RevMan (*Review Manager)* is an easy tool to perform the meta-analyses and generate the graphs (forest plot, funnel plot) in publication standard. Meta-analysis of *CCND1* gene G870A polymorphism (rs9344) was performed by *RevMan 5.3* \[[@B37]\]*.* For statistical models, both fixed model and random model were included in the RevMan. For random models, DerSimonian and Laird random-effects models were used. Odds ratios (ORs) with 95% confidence intervals (95%CIs) were used to assess the strength of association between the *CCND1*-G870A polymorphisms and cancer risk. The pooled OR was evaluated by the Z-test and a *P*-value \<0.05 suggests a significant association.

*I^2^* was used to estimate total variation across studies due to heterogeneity in percentage. A percentage of \<25% was considered as a low level of heterogeneity, 25--50% as a moderate level of heterogeneity, and \>50% as a high level of heterogeneity. *I^2^*\> 50% could suggest heterogeneity and suggest using a random-effect estimate \[[@B38]\]. Otherwise, the fixed-effect model was used to calculate pooled ORs \[[@B39]\].

Software RevMan 5.3 used in this meta-analysis is freely available at <http://community.cochrane.org/tools/review-production-tools/revman-5/revman-5-download>

Statistical analysis {#sec2-7}
--------------------

The association between *CCND1* polymorphism and cancer risk was analyzed by OR with 95%CI in different genetic models: dominant (GA+AA vs GG), recessive (AA vs GG+GA), co-dominant (GA vs GG and AA vs GG), and allelic (A vs G and G vs A). The *P*-value \<0.05 was considered statistically significant. Subgroup analysis was done after stratification of data according to various cancer types.

Heterogeneity was calculated by chi-square test and the extent of heterogeneity was measured by the value of *I^2^* statistic. The OR of different types of genetic models was evaluated by employing the fixed-effect model (when *I^2^* \< 50%) or random-effect model (when *I^2^* \> 50%). Egger's bias test and Begg's funnel plot was used to assess the publication bias \[[@B40],[@B41]\]. It is a well-acknowledged fact that meta-analyses are vulnerable to random errors due to sparse data and repetitive testing of accrued data \[[@B42]\]. Hence, trial sequential analysis (TSA) was performed to minimize the type I error and random error as the present study had smaller sample size. TSA was performed as described previously by Fu et al. (2017) \[[@B43]\]. It was done by using TSA software version 0.9.5.10. (<http://www.ctu.dk/tsa/>) \[[@B44]\] to calculate the required information size (RIS) (meta-analysis sample size) by taking the control event proportion to 25.77%, experimental event proportion 21.55%, a relative risk reduction (RRR) 10%, power 80%, and type I error (α) 5%. The monitoring boundaries were constructed to determine whether present meta-analysis is sufficiently powered and conclusive. Therefore, it is able to reject false-positive reports from meta-analysis \[[@B45]\]. If the Z-curve crosses the TSA boundaries or futility area, there is sufficient information to support the conclusions and further trials are unlikely to change the findings. If the Z-curve does not cross the any of the boundaries or reach the RIS, evidence is insufficient to reach a firm conclusion.

Results {#sec3}
=======

Study characteristics {#sec3-1}
---------------------

Using the *Pubmed* and *Embase* database, a total of 12 studies were searched independently by two investigators (S.K. and N.T.) according to the methodology depicted in flow diagram ([Figure 1](#F1){ref-type="fig"}).

![Methodology flowchart for the selection of studies in the present meta-analysis\
\*Since, data from study PMID 24604328 were extracted twice, hence total articles mentioned are 12 in the text.](bsr-38-bsr20180694-g1){#F1}

Data from one study with PMID 24604328 was extracted twice. All the 12 studies including 1791 cancer cases and 1948 controls met our inclusion criteria. The characteristics of included studies for the present meta-analysis from different cancers are presented in [Table 1](#T1){ref-type="table"}.

###### Characteristics of the studies included in the meta-analysis

  S.No.   PMID         Authors                      Publication year   Country   Ethnicity   Source of control   Cancer type                          Genotyping methods
  ------- ------------ ---------------------------- ------------------ --------- ----------- ------------------- ------------------------------------ --------------------
  1\.     16488657     Sathyan et al. \[[@B22]\]    2006               India     Asian       Hospital based      Oral cancer                          PCR-SSCP
  2\.     17011980     Sobti et al \[[@B25]\]       2006               India     Asian       Hospital based      Lung cancer                          PCR
  3\.     17561354     Jain et al. \[[@B23]\]       2007               India     Asian       Hospital based      Esophageal cancer                    PCR-RFLP
  4\.     18548202     Kaur et al. \[[@B20]\]       2008               India     Asian       Hospital based      Cervical cancer                      PCR-RFLP
  5\.     19489683     Thakur et al. \[[@B19]\]     2009               India     Asian       Hospital based      Cervical cancer                      PCR-RFLP
  6\.     20380574     Gangwar et al. \[[@B26]\]    2010               India     Asian       Hospital based      Urinary bladder cancer               PCR-RFLP
  7\.     21268129     Hussain et al. \[[@B24]\]    2011               India     Asian       Hospital based      Esophageal squamous cell carcinoma   PCR-RFLP
  8\.     20822933     Mandal et al. \[[@B27]\]     2012               India     Asian       Hospital based      Prostate cancer                      PCR-RFLP
  9\.     23354584     Sameer et al. \[[@B29]\]     2013               India     Asian       Hospital based      Colorectal cancer                    PCR-RFLP
  10\.    24604328     Wasson et al. \[[@B21]\]     2014               India     Asian       Hospital based      Breast cancer                        PCR-RFLP
  11\.    24604328\*   Wasson et al. \[[@B21]\]     2014               India     Asian       Hospital based      Breast cancer                        PCR-RFLP
  12\.    25146682     Govatati et al. \[[@B28]\]   2014               India     Asian       Hospital based      Colorectal cancer                    PCR

Abbreviation: RFLP, restriction fragment length polymorphism. \*PMID24604328 taken twice.

Details of genotypic and allelic frequencies of *CCND1* polymorphism is shown in [Table 2](#T2){ref-type="table"}.

###### Distribution of CCND1-G870A genotypes and allelic frequency in cancer cases and controls

  S.No.   PMID                                         Cancer type              Case   Control   Case   Control   Case   Control                                   
  ------- -------------------------------------------- ------------------------ ------ --------- ------ --------- ------ --------- ----- ---- ------ ------ ------ ------
  1\.     16488657                                     Oral cancer              146    137       36     71        39     40        61    36   0.51   0.49   0.49   0.51
  2\.     17011980                                     Lung cancer              151    151       29     87        35     39        69    43   NA     NA     NA     NA
  3\.     17561354                                     Esophageal cancer        151    201       22     76        53     37        111   53   NA     NA     NA     NA
  4\.     18548202                                     Cervical cancer          150    150       33     64        53     30        65    55   NA     NA     NA     NA
  5\.     1948683                                      Cervical cancer          200    200       39     94        67     47        119   34   228    172    187    213
  6\.     20380574                                     Urinary bladder cancer   212    250       48     85        79     58        119   73   243    181    265    235
  7\.     20822933                                     Prostate cancer          192    224       38     65        89     58        93    73   243    141    239    209
  8\.     21268129                                     Esophageal cancer        151    151       20     99        32     56        72    23   163    139    118    184
  9\.     23354584                                     Colorectal cancer        130    160       19     70        41     41        76    43   NA     NA     NA     NA
  10\.    24604328                                     Breast cancer            151    83        33     77        41     07        47    29   159    143    105    61
  11\.    24604328[\*](#T2TFN1){ref-type="table-fn"}   Breast cancer            54     134       15     31        08     18        78    38   47     61     154    114
  12\.    25146682                                     Colorectal cancer        103    107       54     39        10     71        33    03   59     147    39     175

PMID: 24604328 repeated twice in our study. NA, not available.

Meta-analysis of CCND1 G/A polymorphism (rs9344) {#sec3-2}
------------------------------------------------

A total of 12 studies were included in the analysis to evaluate the association between *CCND1* polymorphism and cancer risk in Indian population. The results from meta-analysis of the association between *CCND1* polymorphism (rs9344) and cancer risk in 12 case--control studies are shown in [Figure 2](#F2){ref-type="fig"} and [Table 3](#T3){ref-type="table"}. Values of ORs with 95%CI were as follows: dominant model (GG vs GA+AA: OR = 0.81, 95%CI = 0.60--1.09, *P*=0.17, *I^2^*= 72%); recessive model (GG+GA vs AA: OR = 1.23, 95%CI = 0.96--1.59, *P*=0.11, *I^2^* = 64%); co-dominant model (GG vs AA: OR = 1.35, 95%CI = 0.93-1.97, P = 0.12, I^2^ = 72%); co-dominant model (GG vs GA: OR = 1.16, 95%CI = 0.85--1.59, *P*=0.34, *I^2^* = 69%); allele model (A vs G: OR = 1.20, 95%CI = 1.14--2.85, *P*=0.23, *I^2^* = 82%), and allele model (G vs A: OR = 0.83, 95%CI = 0.62--1.12, *P*=0.23, *I^2^* = 82%) ([Table 3](#T3){ref-type="table"}). If the values of *I^2^* were \>50% then the random-effect model was applied, otherwise fixed-effect model was used to calculate the pooled ORs and 95%CI. In meta-analysis, *P^Z^*\<0.05 was considered statistically significant. Here, we demonstrate that *CCND1* polymorphism G870A (rs9344) is not associated with the risk for overall cancers in Indian population.

###### Forest plots describing the association of *CCND1*-G870A polymorphism with overall cancer risk

(**A**) dominant model (GG vs GA+AA); (**B**) recessive model (GG+GA vs AA); (**C**) co-dominant model (GG vs GA); (**D**) co-dominant model (GG vs AA); (**E**) allele model (A vs G); (**F**) allele model (G vs A).

![](bsr-38-bsr20180694-g2a)

![](bsr-38-bsr20180694-g2b)

###### Meta-analysis results based on different genetic models

  S.No.   Category                        OR     \[95%CI\]        *P*^*Z*^   *P^H^*      *I^2^* (%)   Statistical method
  ------- ------------------------------- ------ ---------------- ---------- ----------- ------------ --------------------
  1\.     Dominant model (GG vs GA+AA)    0.81   \[0.60--1.09\]   0.17       \<0.0001    72%          Random
  2\.     Recessive model (GG+GA vs AA)   1.23   \[0.96--1.59\]   0.11       0.001       64%          Random
  3\.     Co-dominant model (AA vs GG)    1.35   \[0.93, 1.97\]   0.12       \<0.0001    72%          Random
  4\.     Co-dominant model (GA vs GG)    1.16   \[0.85, 1.59\]   0.34       0.0002      69%          Random
  5\.     Allele model (A vs G)           1.20   \[1.14--2.85\]   0.23       \<0.00001   82%          Random
  6\.     Allele model (G vs A)           0.83   \[0.62--1.12\]   0.23       \<0.00001   82%          Random

Abbreviations: P^H^, P value for heterogeneity; P^Z^, P value for Z-test.

On subgroup analysis stratified according to cancer types showed significant association of *CCND1* polymorphism and increased breast cancer risk in dominant model (GG vs GA+AA: OR = 2.75, 95%CI = 1.54--4.90, *P*=0.0006), allelic model (G vs A: OR = 1.63, 95%CI = 1.22--2.19, *P*=0.001). A statistically significant association with esophageal cancer risk was observed in recessive (GG+GA vs AA: OR = 1.51, 95%CI = 1.05--2.16, *P*=0.03) and co-dominant model (GG vs AA: OR = 2.51, 95%CI = 1.10--5.71, *P*=0.03). An increased risk for colorectal cancer was detected under both the co-dominant models (GG vs AA: OR = 2.46, 95%CI = 1.34--4.51, *P*=0.004 and GG vs GA: OR = 1.74, 95%CI = 1.14--2.67, *P*=0.01). Contrary to this, none of the genetic model reported a statistically significant association with cervical cancer risk. Although a non-significant association was observed in recessive model (GG+GA vs AA: OR = 1.52, 95%CI = 0.60--3.90, *P*=0.38) and co-dominant model (GG vs AA: OR = 1.45, 95%CI = 0.55--3.85, *P*=0.46) with reference to *CCND1* polymorphism (rs9344) ([Figures 3](#F3){ref-type="fig"}--[6](#F6){ref-type="fig"} and [Table 4](#T4){ref-type="table"}).

###### Forest plots describing the association of *CCND1*-G870A polymorphism with breast cancer risk

(**A**) dominant model (GG vs GA+AA); (**B**) recessive model (GG+GA vs AA); (**C**) co-dominant model (GG vs GA); (**D**) co-dominant model (GG vs AA); (**E**) allele model (A vs G); (**F**) allele model (G vs A).

![](bsr-38-bsr20180694-g3a)

![](bsr-38-bsr20180694-g3b)

![Forest plots describing the association of *CCND1-G870A* polymorphism with colorectal cancer risk\
(**A**) dominant model (GG vs GA+AA); (**B**) recessive model (GG+GA vs AA); (**C**) co-dominant model (GG vs GA); (**D**) co-dominant model (GG vs AA).](bsr-38-bsr20180694-g4){#F4}

![Forest plots describing the association of *CCND1*-G870A polymorphism with esophageal cancer risk\
(**A**) dominant model (GG vs GA+AA); (**B**) recessive model (GG+GA vs AA); (**C**) co-dominant model (GG vs GA); (**D**) co-dominant model (GG vs AA).](bsr-38-bsr20180694-g5){#F5}

![Forest plots describing the association of *CCND1*-G870A polymorphism with cervical cancer risk\
(**A**) dominant model (GG vs GA+AA); (**B**) recessive model (GG+GA vs AA) (**C**) co-dominant model (GG vs GA); (**D**) co-dominant model (GG vs AA).](bsr-38-bsr20180694-g6){#F6}

###### Subgroup analysis: meta-analysis results according to the type of cancer

  Subgroup                        OR     (95%CI)        *P^Z^*       *P*^*H*^   I^*2*^ (%)   Effects model
  ------------------------------- ------ -------------- ------------ ---------- ------------ ---------------
  **Breast cancer**                                                                          
  Dominant model (GG vs GA+AA)    2.75   (1.54--4.90)   **0.0006**   0.73       0%           Fixed
  Recessive model (GG+GA vs AA)   0.59   (0.37--0.95)   **0.03**     0.38       0%           Fixed
  Co-dominant model (GG vs GA)    0.41   (0.23--0.74)   **0.003**    0.60       0%           Fixed
  Co-dominant model (GG vs AA)    0.28   (0.14--0.56)   **0.0003**   0.81       0%           Fixed
  Allele model (A vs G)           0.61   (0.46--0.82)   **0.001**    0.68       0%           Fixed
  Allele model (G vs A)           1.63   (1.22--2.19)   **0.001**    0.68       0%           Fixed
  **Colorectal cancer**                                                                      
  Dominant model (GG vs GA+AA)    0.53   (0.35--0.80)   **0.002**    0.78       0%           Fixed
  Recessive model (GG+GA vs AA)   1.81   (0.66--4.99)   0.25         0.13       56%          Random
  Co-dominant model (GG vs GA)    1.74   (1.14--2.67)   **0.01**     0.58       0%           Fixed
  Co-dominant model (GG vs AA)    2.46   (1.34--4.51)   **0.004**    0.32       0%           Fixed
  **Esophageal cancer**                                                                      
  Dominant model (GG vs GA+AA)    0.44   (0.15--1.26)   0.13         0.010      85%          Random
  Recessive model (GG+GA vs AA)   1.51   (1.05--2.16)   **0.03**     0.98       0%           Fixed
  Co-dominant model (GG vs GA)    2.11   (0.65--6.88)   0.22         0.005      87%          Random
  Co-dominant model (GG vs AA)    2.51   (1.10--5.71)   **0.03**     0.09       64%          Random
  **Cervical cancer**                                                                        
  Dominant model (GG vs GA+AA)    0.92   (0.64--1.32)   0.64         0.34       0%           Fixed
  Recessive model (GG+GA vs AA)   1.52   (0.60--3.90)   0.38         0.005      87%          Random
  Co-dominant model (GG vs GA)    0.93   (0.63--1.37)   0.71         0.88       0%           Fixed
  Co-dominant model (GG vs AA)    1.45   (0.55--3.85)   0.46         0.02       81%          Random

Abbreviations: *P^Z^, P*-value for Z-test; *P^H^, P*-value for heterogeneity. Statistically significant values shown in bold.

Heterogeneity measurement {#sec3-3}
-------------------------

Heterogeneity value depicted as *I^2^* was calculated for different genetic models and presented in [Table 3](#T3){ref-type="table"}. Heterogeneity was observed in all the genotypic and allelic models. For dominant model: GG vs GA+AA: *I^2^* = 72%, *P* for heterogeneity \<0.0001; recessive model: GG+GA vs AA: *I^2^* = 64%, *P* for heterogeneity = 0.001; co-dominant model: GG vs AA: *I^2^* = 69%, *P* for heterogeneity = 0.0002; co-dominant model: GG vs GA: *I^2^* = 72%, *P* for heterogeneity = 0.0001; allelic model: A vs G: *I^2^* = 82%, *P* for heterogeneity \<0.00001 and allelic model: G vs A: *I^2^* = 82%, *P* for heterogeneity \<0.00001 were noted, respectively ([Table 3](#T3){ref-type="table"}).

Publication bias {#sec3-4}
----------------

Funnel plots were used in random-effect and fixed-effect models respectively to detect the publication bias. A relatively symmetric distribution in the funnel plot was observed, which indicates that there is no significant publication bias in the included studies ([Figure 7](#F7){ref-type="fig"}).

![Funnel plot assessing publication bias in recessive model (GG+GA vs AA)](bsr-38-bsr20180694-g7){#F7}

TSA {#sec3-5}
---

The TSA for association between CCND1 polymorphism (rs9344) and overall cancer risk showed that only conventional boundary was crossed by Z-curve, however, it neither crossed the TSA boundary nor the futility area. And the total sample size (3739) did not reach the RIS (11375) ([Figure 8](#F8){ref-type="fig"}). This result indicates that present meta-analysis is inconclusive at this level. Further studies/trials are needed to make this association valid.

![TSA of association of *CCND1* polymorphism (rs9344) and overall cancer risk in Indian population from 12 studies\
The cumulative Z-curve was constructed by using random-effect model. We calculated α-spending adjusted RIS of 11375 patients using α = 0.05 (two-sided), β = 0.20 (power = 80%). *Note: Z-curve (blue); Conventional boundary (green); TSA boundary (red)*.](bsr-38-bsr20180694-g8){#F8}

Discussion {#sec4}
==========

*CCND1* is key driver of normal cell cycle regulation and genetic variation in this gene has been reported in many types of cancers. A SNP G870A (rs9344) located on exon-4--intron boundary of *CCND1* has been studied extensively in several cancer types. Several reports from different parts of the world have been published with reference to *CCND1* polymorphism and risk of various types of cancers including cervical, prostate, colorectal, urinary bladder, squamous cell carcinoma of the head and neck etc. \[[@B46]\]. Investigators from India also tried to explore the association of CCND1 polymorphism and susceptibility to different cancer types including cervical, breast, oral, esophageal, lung, urinary bladder, prostate, and colorectal \[[@B19]\]. However, these reports are conflicting thus we performed meta-analysis on the literature available in order to provide more accurate information on the role of *CCND1* G870A (rs9344) polymorphism and overall cancer risk in Indian population. Although, various meta-analyses on individual cancer susceptibility have been published globally \[[@B30]\]. Pabalan et al. (2008) \[[@B51]\], performed a meta-analysis on role of *CCND1* polymorphism in different types of cancers and populations. However, a comprehensive data are lacking from India with overall cancer risk. Hence, we have designed the present study focussed on Indian population.

The present meta-analysis, contained a total of 12 studies comprising 1791 cancer cases and 1948 controls \[[@B19]\] showed the lack of significant association between *CCND1* G870A polymorphism (rs9344) and overall cancer risk in all the genetic models. These findings are consistent with the result of another study by Luo et al. (2016) \[[@B52]\], which ruled out the involvement of *CCND1* polymorphism (G870A) with the risk of hepatocellular carcinoma. In the similar lines, study by Zheng et al. (2015) \[[@B53]\] suggested that *CCND1* polymorphism may not be associated with the risk of prostate cancer. Similarly, Wang et al. (2018) \[[@B54]\] also found no significant association between the let-7i rs10877887 and let-7a-1/let-7f-1/let-7d rs13293512 polymorphisms and overall cancer risk. In disagreement with our findings a meta-analysis by Pabalan et al. (2008) \[[@B51]\], showed an increased cancer risk associated with *CCND1*-A870G polymorphism in the human population. Another study by Qin et al. (2014) \[[@B55]\] also indicated that *CCND1* polymorphism may increase the risk of non-Hodgkin lymphoma but it was not true in case of leukemia. On the identical lines, Lin et al. (2014) \[[@B56]\] too observed the lack of association between *CCND1* polymorphism (G870A) and head and neck cancer, however; they found that smokers carrying 'A' allele or 'AA' genotype for rs9344 SNP located on *CCND1* may be at higher risk to head and neck cancer development.

Our subgroup analysis showed an increased risk (1.52-fold) for cervical cancer development but this association could not attain the limits of statistical significance (*P*=0.38). The possible explanation for this observation may be the small sample size of contributing studies. No promising association of this SNP has been established with the development of cervical cancer in Caucasian population by Yang et al. (2015) \[[@B57]\]. In another study, no significant association was reported between the *CCND1* SNP (rs9344) and overall risk for cervical cancer in the Asian population but on stratification analysis by race, individuals carrying the AA or AA/AG genotypes showed a significant higher risk in comparison with GG carriers \[[@B32]\]. In parallel to the findings from the present study, Hu et al. (2014) \[[@B30]\], also did not find the association of *CCND1* G870A polymorphism and cervical cancer risk amongst different ethnic groups including Asian, Caucasian, and mixed in a cumulative meta-analysis.

Additionally, a significant association between *CCND1* polymorphism and increased risk for breast and esophageal cancer has been established. Similar to our results, Sergentanis and Economopoulos (2011) \[[@B58]\] found that the 'A' allele of the *CCND1* G870A polymorphism is associated with higher risk for breast cancer. These findings are further strengthened by another meta-analyses conducted by Lu et al. (2009) \[[@B59]\] and Cui et al. (2012) \[[@B60]\] that showed the association of AA genotype of *CCND1* G870A polymorphism with breast cancer susceptibility. Similarly, Soleimani et al. (2016) \[[@B61]\] showed a significant association between *CCND1* G870A polymorphism and breast cancer risk but in Caucasians. A meta-analysis conducted Wen et al. (2014) \[[@B62]\] supported our data that *CCND1* G870A polymorphism is a potential risk factor in the development of esophageal cancer. Other related meta-analysis by Cai et al. (2013) \[[@B63]\] is not in agreement with our findings and showed lack of potential association between *CCND1* G870A polymorphism and esophageal cancer risk. Likewise, Tang et al. (2015) \[[@B64]\], also observed similar results describing that *CCND1* SNP rs9344 is not having role in esophageal squamous cell carcinoma.The present study suggests that there is a significant correlation between this polymorphism and increased risk of colorectal cancer amongst Indian population. Recently, Xu et al. (2016) \[[@B34]\] suggested that this SNP may increase the risk for developing colorectal cancer with special emphasis to sporadic colorectal cancer in Caucasian population. The study by Jiang et al. (2006) \[[@B65]\] suggested that the *CCND1* G870 AA genotype may increase the colorectal cancer risk compared with the GG+AG genotype (OR = 1.56, 95%CI = 1.10--2.21) in an Indian population. Similarly, Zhang et al. (2016) \[[@B33]\], suggested that *CCND1* polymorphism is a risk factor for gastric cancer in Caucasians. According to the literature search, Dai et al. (2016) \[[@B35]\] also tried to establish the association between *CCND1* polymorphism (rs678653) located on the 3′-UTR and susceptibility to cancer, but they have not studied the polymorphism under investigation G870A (rs9344).

The present study had some limitations, first, all of the included studies were hospital based which may not represent the true population. Second, environmental factors like smoking, use of alcohol, and infections with viruses were not included in the present meta-analysis. Finally, the sample size was reasonably small, which may be the reason for controversial results.

Conclusion {#sec5}
==========

In conclusion, present meta-analysis showed that *CCND1* SNP (rs9344) may not serve as a risk factor for overall cancer susceptibility in Indian population. However, a significant association between *CCND1* SNP and increased risk for breast, esophageal, and colorectal cancer was found on subgroup analysis. Moreover, a non-significant increased risk for cervical cancer in relation to *CCND1* polymorphism was observed in Indian population. Thus, *CCND1* G870A (rs9344) polymorphism has a potential to be served as a prognostic biomarker for breast, esophageal, and colorectal cancer in Indian population. Still, larger and well-designed studies including other risk factors are warranted in future to validate the findings from present analysis.
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